Oxurion Receives EUR 1.5 Million under Amended Atlas Funding Program; Total of EUR 3.5 Million in Unconditional Funding Allowing Company to Achieve Topline Data from KALAHARI Trial

25.10.2023 - Leuven, BELGIUM, Boston, MA, US – October 25, 2023 – 8 am CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal ...

Related Keywords

Belgium ,United States ,Leuven ,Region Flamande ,Boston ,Massachusetts ,Tom Graney ,Michael Dillen ,Maryt Conway ,Conway Communications ,Company Annual ,Funding Program ,Subscription Agreement ,Euronext Brussels ,Oxurion Chart ,Xurion Kurs ,Xurion Aktie ,